Matthew Rabinowitz sold $38M of NTRA
EXECUTIVE CHAIRMAN at Natera, Inc.. 200,000 shares at an average of $191.42, traded Mar 12, 2026, filed Mar 16, 2026.
Score components
- +20RoleChair
- +25Trade size$38.3M at market
- 0Share of holdings soldSold 8.4% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +4.8%, 3m +9.8%, 6m +72.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001646382-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 12, 2026 | MOption exercise Common Stock10b5-1 | +75,000 | $9.59 | $719k | 2,385,772 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Common Stock10b5-1 | -8,091 | $186.75 | $1.5M | 2,377,681 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Common Stock10b5-1 | -5,809 | $187.52 | $1.1M | 2,371,872 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Common Stock10b5-1 | -6,451 | $188.52 | $1.2M | 2,365,421 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Common Stock10b5-1 | -2,886 | $189.64 | $547k | 2,362,535 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Common Stock10b5-1 | -22,063 | $190.53 | $4.2M | 2,340,472 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Common Stock10b5-1 | -9,896 | $191.55 | $1.9M | 2,330,576 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Common Stock10b5-1 | -8,579 | $192.79 | $1.7M | 2,321,997 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Common Stock10b5-1 | -7,043 | $193.58 | $1.4M | 2,314,954 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Common Stock10b5-1 | -4,082 | $194.57 | $794k | 2,310,872 | Mar 16, 2026 |
| Mar 12, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $195.32 | $20k | 2,310,772 | Mar 16, 2026 |
| Mar 13, 2026 | MOption exercise Common Stock10b5-1 | +75,000 | $9.59 | $719k | 2,385,772 | Mar 16, 2026 |
| Mar 13, 2026 | SOpen-market sale Common Stock10b5-1 | -17,037 | $187.63 | $3.2M | 2,368,735 | Mar 16, 2026 |
| Mar 13, 2026 | SOpen-market sale Common Stock10b5-1 | -21,476 | $188.54 | $4.0M | 2,347,259 | Mar 16, 2026 |
| Mar 13, 2026 | SOpen-market sale Common Stock10b5-1 | -21,504 | $189.50 | $4.1M | 2,325,755 | Mar 16, 2026 |
| Mar 13, 2026 | SOpen-market sale Common Stock10b5-1 | -13,883 | $190.46 | $2.6M | 2,311,872 | Mar 16, 2026 |
| Mar 13, 2026 | SOpen-market sale Common Stock10b5-1 | -1,100 | $191.22 | $210k | 2,310,772 | Mar 16, 2026 |
| Mar 16, 2026 | MOption exercise Common Stock10b5-1 | +50,000 | $9.59 | $480k | 2,360,772 | Mar 16, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $190.07 | $19k | 2,360,672 | Mar 16, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -300 | $190.68 | $57k | 2,360,372 | Mar 16, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -900 | $192.43 | $173k | 2,359,472 | Mar 16, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -2,300 | $194.17 | $447k | 2,357,172 | Mar 16, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -4,875 | $195.42 | $953k | 2,352,297 | Mar 16, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -24,814 | $196.23 | $4.9M | 2,327,483 | Mar 16, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -16,457 | $197.22 | $3.2M | 2,311,026 | Mar 16, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -254 | $198.02 | $50k | 2,310,772 | Mar 16, 2026 |
| Mar 12, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -75,000 | $0.00 | $0 | 225,000 | Mar 16, 2026 |
| Mar 13, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -75,000 | $0.00 | $0 | 150,000 | Mar 16, 2026 |
| Mar 16, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -50,000 | $0.00 | $0 | 100,000 | Mar 16, 2026 |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $526k 1,273 shares | -1% | |
| 40Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $1.2M 3,000 shares | -3% | |
| 55Moderate | Natera, Inc. | Jonathan Sheena director, other | $7.0M 18,064 shares | -100% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $3.2M 9,150 shares | -4% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $35M 102,000 shares | -5% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $16M 50,000 shares | -2% | |
| 39Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $545k 1,698 shares | -2% | |
| 45Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $5.9M 18,160 shares | -14% | |
| 40Moderate | Natera, Inc. | John Fesko PRESIDENT, CHIEF BUS. OFFICER | $2.1M 6,517 shares | -3% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $2.0M 6,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.